Triazole-substituted phenylboronic acids as tunable lead inhibitors of KPC-2 antibiotic resistance

Eur J Med Chem. 2022 Oct 5:240:114571. doi: 10.1016/j.ejmech.2022.114571. Epub 2022 Jun 28.

Abstract

Inhibition of β-lactamases is a promising strategy to overcome antimicrobial resistance to commonly used β-lactam antibiotics. Boronic acid derivatives have proven to be effective inhibitors of β-lactamases due to their direct interaction with the catalytic site of these enzymes. We synthesized a series of phenylboronic acid derivatives and evaluated their structure-activity relationships as Klebsiella pneumoniae carbapenemase (KPC-2) inhibitors. We identified potent KPC-2 inhibitors 2e & 6c (Ki = 0.032 μM and 0.038 μM, respectively) that enhance the activity of cefotaxime in KPC-2 expressing Escherichia coli. The measured acid dissociation constants (pKa) of selected triazole-containing phenylboronic acids was broad (5.98-10.0), suggesting that this is an additional property of the compounds that could be tuned to optimize the target interaction and/or the physicochemical properties of the compounds. These findings will help to guide the future development of boronic acid compounds as inhibitors of KPC-2 and other target proteins.

Keywords: Antimicrobial resistance (AMR); KPC-2; Phenylboronic acids; SAR.

MeSH terms

  • Anti-Bacterial Agents / metabolism
  • Anti-Bacterial Agents / pharmacology
  • Bacterial Proteins / metabolism
  • Boronic Acids / chemistry
  • Drug Resistance, Microbial
  • Escherichia coli
  • Klebsiella pneumoniae*
  • Microbial Sensitivity Tests
  • Triazoles* / pharmacology
  • beta-Lactamase Inhibitors / metabolism
  • beta-Lactamase Inhibitors / pharmacology
  • beta-Lactamases / metabolism

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Boronic Acids
  • Triazoles
  • beta-Lactamase Inhibitors
  • beta-Lactamases
  • carbapenemase
  • benzeneboronic acid